METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma

已完结 10 由诗奕发布于 2024/11/29 20:06:28

DOI:10.1016/j.canlet.2023.216122
作者：Lina Wang ,?Qingxia Yang ,?Qianying Zhou ,?Fei Fang ,?Kai Lei ,?Ziqin Liu ,?Gaomin Zheng ,?Lefan Zhu ,?Jihui Huo ,?Xiaoxing Li ,?Sui Peng ,?Ming Kuang ,?Shuibin Lin ,?Manling Huang ,?Lixia Xu
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Lenvatinib is emerging as the first-line therapeutic option for advanced hepatocellular carcinoma (HCC), but drug resistance remains a major hurdle for its long-term therapy efficiency in cl

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Computer-Guided Engineered Endo- and Exocleaving Glycosidase for Significantly Improving Production of Ginsenoside F1